<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341638</url>
  </required_header>
  <id_info>
    <org_study_id>CV006-003</org_study_id>
    <nct_id>NCT02341638</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maximum Age:

      Part A SAD 65 years

      Part B MAD 75 years

      Part C MAD Japanese 75 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
    <description>Serious adverse event (SAE)
Adverse event (AE)
Electrocardiogram (ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours (C24) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T-HALF) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC accumulation index (AI_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551; ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR_Cmax of BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR_AUC(INF) of BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight [MR_AUC(INF)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR_AUC(0-T) of BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR_AUC(TAU) of BMT-162853, BMT-162856, and BMT-181551</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple doses of BMS-986141 and aspirin in healthy subjects</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
    <description>Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of multiple doses of BMS-986141 and aspirin in healthy subjects</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
    <description>Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of BMS-986141 and itraconazole in healthy subjects</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
    <description>Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of BMS-986141 and itraconazole in healthy subjects</measure>
    <time_frame>Up to 30 days post discontinuation of dosing or last participation in the study</time_frame>
    <description>Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Part A Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 4: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 5: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 6: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 7: BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Panel 8: BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 or Placebo by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Panel 1: BMS-986141 and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 and Aspirin by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Panel 1: Placebo matching BMS-986141 and Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BMS-986141 placebo and Aspirin by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E Panel 1: BMS-986141 and Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986141 and Itraconazole by mouth as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986141</intervention_name>
    <arm_group_label>Part A Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 4: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 5: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 6: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 7: BMS-986141</arm_group_label>
    <arm_group_label>Part A Panel 8: BMS-986141</arm_group_label>
    <arm_group_label>Part B Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part B Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part B Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part D Panel 1: BMS-986141 and Aspirin</arm_group_label>
    <arm_group_label>Part E Panel 1: BMS-986141 and Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 4: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 5: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part A Panel 6: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part B Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part B Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part B Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 1: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 2: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part C Panel 3: BMS-986141 or Placebo</arm_group_label>
    <arm_group_label>Part D Panel 1: Placebo matching BMS-986141 and Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Part D Panel 1: BMS-986141 and Aspirin</arm_group_label>
    <arm_group_label>Part D Panel 1: Placebo matching BMS-986141 and Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <arm_group_label>Part E Panel 1: BMS-986141 and Itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          1. Healthy male and female subjects as determined by no clinically significant deviation
             from normal in medical history, physical examination, ECGs, and clinical laboratory
             determinations

          2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/[height(m)]2

          3. Women who are not of childbearing potential (i.e., who are postmenopausal or
             surgically sterile) and men, ages 18 to 75, inclusive

        Exclusion Criteria:

          1. Concurrent or use within 2 weeks of study drug administration, of marketed or
             investigational, drugs as specified in protocol

          2. Other protocol-defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

